is shelving its highly anticipated cystic fibrosis drug candidate, SION-719, after it failed to meet...
Why Sionna Therapeutics Stock Is Crashing 91% to a Record Low
is shelving its highly anticipated cystic fibrosis drug candidate, SION-719, after it failed to meet the key endpoint in a proof-of-concept trial.
Author: Barron's
Read Original Article